

Influenza B Yamagata lineage candidate vaccine viruses and potency testing reagents for vaccine development and production for the southern hemisphere 2014

26 September 2013

Candidate vaccine viruses

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Massachusetts/2/2012	Wild type virus			CDC, USA
	NYMC BX-51B#	Classical	NYMC, USA	CDC, USA NYMC, USA
	NYMC BX-51C##	Classical	NYMC, USA	CDC, USA NYMC, USA

B/Panama/45/90 backbone parent

B/Lee/40 and B/Panama/45/90 backbone parents

Institutes contact details for candidate vaccine viruses' orders/information:

CDC: xxu@cdc.gov

NYMC: doris_bucher@nymc.edu

Reference antigens (freeze-dried)

Starting materials			Ref Ag	Unitage	Available from
Parent virus	CVV	Egg or Cell	Lot #	(µgHA/mL)	
*B/Massachusetts/2/2012	Wildtype		13/134	35	NIBSC
	NYMC BX-51B		13/106	60	NIBSC
			2013/94B	77	TGA

***new reference antigen**

Sheep antisera

Purified HA from		Order	Available from
Parent virus	Egg or Cell	Lot #	
*B/Massachusetts/2/2012	Egg	AS405	TGA

***new reference antisera**

The above-listed potency testing reagents have been developed with support from manufacturers, and calibrated by the Essential Regulatory Laboratories (ERLs) that provide advice to WHO as part of the influenza vaccine virus selection and development process.

ERLs contact details for reagents orders/information:

NIBSC: standards@nibsc.org
 TGA: influenza.reagents@tga.gov.au
 NIID: flu-vaccine@nih.go.jp
 CBER/FDA: Rajesh.Gupta@fda.hhs.gov

For general enquiries, please contact gisrs-whohq@who.int

For other candidate vaccine viruses and potency testing reagents, please go to <http://www.who.int/influenza/vaccines/virus/en>